Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck

Head and Neck

Volumn 25, Issue 6, 2003, Pages 464-474

  Neuchrist, Csilla ^a   Erovic, Bohan M ^a   Handisurya, Allesandra ^a   Fischer, Michael B ^a   Steiner, Georg E ^a   Hollemann, David ^a   Gedlicka, Claudia ^a   Saaristo, A ^b   Burian, Martin ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Flt4; HNSCC; Immunohistochemistry; Lymph angiogenesis; Microvessel; Tumor; VEGF C

Indexed keywords

MESSENGER RNA; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ANGIOGENESIS; ANTIBODY LABELING; ARTICLE; CLINICAL ARTICLE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR RECURRENCE; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; ENDOTHELIAL GROWTH FACTORS; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 0037936730     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.10235     Document Type: Article

References (41)

1. Petruzzelli GJ. The biology of tumor invasion, angiogenesis and lymph node metastasis. ORL J Otorhinolaryngol Relat Spec 2000;62:178-185.
2. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. Faseb J 1999;13:9-22.
3. Frelin C, Ladoux A, D'Angelo G. Vascular endothelial growth factors and angiogenesis. Ann Endocrinol Paris 2000;61:70-74.
4. Weidner N. angiogenesis as a predictor of clinical outcome in cancer patients. Hum Pathol 2000;31:403-405.
5. Fontanini G, Vignati S, Lucchi M, et al. Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression [see comments]. Br J Cancer 1997;75:1295-1301.
6. Gleich LL, Biddinger PW, Duperier FD, Gluckman JL. Tumor angiogenesis as a prognostic indicator in T2-T4 oral cavity squamous cell carcinoma: a clinical-pathologic correlation. Head Neck 1997;19:276-280.
7. Neuchrist C, Quint C, Pammer A, Burian M. Vascular endothelial growth factor (VEGF) and microvessel density in squamous cell carcinomas of the larynx: an immunohistochemical study. Acta Otolaryngol 1999;119:732-738.
8. Salven P, Heikkila P, Anttonen A, Kajanti M, Joensuu H. Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance. Mod Pathol 1997;10:1128-1133.
9. Zatterstrom UK, Brun E, Willen R, Kjellen E, Wennerberg J. Tumor angiogenesis and prognosis in squamous cell carcinoma of the head and neck. Head Neck 1995;17:312-318.
10. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999;5:1359-1364.
11. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999;59:99-106.
12. Kubo H, Fujiwara T, Jussila L, et al. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood 2000;96:546-553.
13. Denhart BC, Guidi AJ, Tognazzi K, Dvorak HF, Brown LF. Vascular permeability factor/vascular endothelial growth factor and its receptors in oral and laryngeal squamous cell carcinoma and dysplasia. Lab Invest 1997;77:659-664.
14. Claffey KP, Robinson GS. Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Cancer Metastasis Rev 1996;15:165-176.
15. Breiteneder-Geleff S, Soleiman A, Kowalski H, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 1999;154:385-394.
16. Chomczynski P, Sacch N. Single-step method of RNA Isolation by acid guanidinium thiocyanate-phenolchloroform extraction. Anal Biochem 1987;162:156-159.
17. Andre T, Kotelevets L, Vaillant JC, et al. Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int J Cancer 2000;86:174-181.
18. Kociok N, Heppekausen H, Schraermeyer U, et al. The mRNA expression of cytokines and their receptors in cultured iris pigment epithelial cells: a comparison with retinal pigment epithelial cells. Exp Eye Res 1998;67:237-250.
19. Partanen TA, Alitalo K, Miettinen M. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer 1999;86:2406-2412.
20. Fernandez Pujol B, Lucibello FC, Zuzarte M, Lutjens P, Muller R, Havemann K. Dendritic cells derived from peripheral monocytes express endothelial markers and in the presence of angiogenic growth factors differentiate into endothelial-like cells. Eur J Cell Biol 2000;80:99-110.
21. Zangani D, Darcy KM, Masso-Welch PA, Bellamy ES, Desole MS, Ip MM. Multiple differentiation pathways of rat mammary stromal cells in vitro: acquisition of a fibroblast, adipocyte or endothelial phenotype is dependent on hormonal and extracellular matrix stimulation. Differentiation 1999;64:91-101.
22. Ziegler BL, Valtieri M, Porada GA, et al. KDR receptor: a key marker defining hematopoietic stem cells. Science 1999;285:1553-1558.
23. Shushanov S, Bronstein M, Adelaide J, et al. VEGFc and VEGFR3 expression in human thyroid pathologies. Int J Cancer 2000;86:47-52.
24. Yonemura Y, Fushida S, Bando E, et al. Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer. Eur J Cancer 2001;37:918-923.
25. Lymboussaki A, Olofsson B, Eriksson U, Alitalo K. Vascular endothelial growth factor (VEGF) and VEGF-C show overlapping binding sites in embryonic endothelia and distinct sites in differentiated adult endothelia. Circ Res 1999;85:992-999.
26. Williams JK, Carlson GW, Cohen C, Derose PB, Hunter S, Jurkiewicz MJ. Tumor angiogenesis as a prognostic factor in oral cavity tumors. Am J Surg 1994;168:373-380.
27. Eisma RJ, Spiro JD, Kreutzer DL. Vascular endothelial growth factor expression in head and neck squamous cell carcinoma. Am J Surg 1997;174:513-517.
28. Herold-Mende C, Andl T, Laemmler F, Reisser C, Mueller MM. [Functional expression of vascular endothelial growth factor receptor Flt-1 on squamous cell carcinoma of the head and neck]. HNO 1999;47:706-711.
29. Neuchrist C, Erovic B, Handisurya A, et al. VEGFR2 (Vascular endothelial growth factor receptor 2) expression in squamous cell carcinomas of the head and neck. Laryngoscope 2001;111:1834-1841.
30. Janot F, el-Naggar AK, Morrison RS, Liu TJ, Taylor DL, Clayman GL. Expression of basic fibroblast growth factor in squamous cell carcinoma of the head and neck is associated with degree of histologic differentiation. Int J Cancer 1995;64:117-123.
31. Quint C, Neuchrist C, Breitschopf H, Pammer J, Burian M. Expression of basic fibroblast growth factor in squamous cell carcinomas of the larynx - examination by in situ hybridization. Onkologie 1999;22:41-46.
32. Valtola R, Salven P, Heikkila P, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 1999;154:1381-1390.
33. Yonemura Y, Endo Y, Fujita H, et al. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res 1999;5:1823-1829.
34. Ohta Y, Shridhar V, Bright RK, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999;81:54-61.
35. Pajusola K, Aprelikova O, Korhonen J, et al. FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines [published erratum appears in Cancer Res 1993 Aug 15;53:3845]. Cancer Res 1992;52:5738-5743.
36. Saaristo A, Partanen TA, Arola J, et al. Vascular endothelial growth factor-C and its receptor VEGFR-3 in the nasal mucosa and in nasopharyngeal tumors. Am J Pathol 2000;157:7-14.
37. Kappel A, Ronicke V, Damert A, Flamme I, Risau W, Breier G. Identification of vascular endothelial growth factor (VEGF) receptor-2 (Flk-1) promoter/enhancer sequences sufficient for angioblast and endothelial cell-specific transcription in transgenic mice. Blood 1999;93:4284-4292.
38. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-248.
39. Jacquemier J, Mathoulin-Portier MP, Valtola R, et al. Prognosis of breast-carcinoma lymphogenesis evaluated by immunohistochemical investigation of vascularendothelial-growth-factor receptor 3. Int J Cancer 2000;89:69-73.
40. Borg JP, deLapeyriere O, Noguchi T, Rottapel R, Dubreuil P, Birnbaum D. Biochemical characterization of two isoforms of FLT4, a VEGF receptor-related tyrosine kinase. Oncogene 1995;10:973-984.
41. Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001;7:186-191.